Introduction
advanced stage or metastatic disease.
[1] However, some patients are unable to achieve a complete response.
[2]
Germ cell tumors respond generally very well to Many prognostic factors including the stage of disease, [3] conventional or to salvage chemotherapy, even in histopathology, [4] the localization site of the primary tumor, [5] serum alfa-feto protein (AFP) and β-HCG levels, [6] [7] [8] visceral metastasis sites and the number of metastatic sites [6] are examined up-to-date especially in early stage tumors either to preview the outcome or to select the best treatment modality for patients carrying poor prognosis. In the present study, we retrospectively analyzed some prognostic factors and the outcome of patients with stage II and III nonseminomatous germ cell tumors treated between 1993 and 2002 at our institution.
Materials and Methods

Patients' characteristics
Patients' characteristics are given in Table 1 . A total of Cancer Collaborative Group (IGCCCG) [ Table 1 ].
[10]
(n) (%) number
Chemotherapy regimens 3 5 < 20 58
All patients were given the same initial BEP the third and fourth year and annually thereafter.
Terato carcinoma 20 34
Patients with residual retroperitoneal lymphadenopathy, despite normal serum tumor marker levels underwent 
Histopathologic evaluation
All archival tissue blocks from each tumor were initially 58 patients (19-45 years old) with stage II (36 patients) and stage III (22 patients) nonseminomatous germ cell tumors treated with chemotherapy at our university hospital between 1993 and 2002 were retrospectively analyzed. Most of the patients underwent surgery at different centers and then were referred to our center for chemotherapy application. All data were retrieved by the same physician. At initial presentation, clinical staging was done according to AJCC Cancer Staging [9] with computed tomography of the chest, abdomen and pelvis; as well as preoperative serum tumor marker (AFP and β-HCG) levels were noted for each patient. Initial localization sites of the tumor, metastasis sites (lung versus other than lung) and tumor response to first-line chemotherapy were also noted. Patients were classified as good, intermediate and poor Other than lung 14 24
Number of death 17
Stage II 5 9
Stage III 12 21
checked by hematoxylin and eosin-stained sections to select the representative block with available tissue for immunocytochemical staining. Two same pathologists who did not know the initial stage of disease examined a 4-µm thick section from each formalin-fixed paraffinembedded tumor.
Statistics
The differences between the groups were tested using 
Results
Patients and histopathologic findings
Thirty-six patients (62%) had stage II and 22 patients (38%) had stage III disease. In 45 patients (78%), the tumor arose from the testis, whereas in 13 patients 0.003 and p: 0.004), the relapse site (lung vs other site than lung) (p: 0. complete response has occurred in 31%, 11% and 0% The aims of our study were to examine primarily the outcome and secondarily the prognostic factors in stage II and III nonseminomatous germ cell tumors.
In our study, we found that, five-year overall survival II and III disease, respectively. However, according to risk groups, five-year overall survival rates were 97%, 75% and 7%; and five-year disease-free survival rates were 83%, 34% and 7% in good risk, intermediate risk and poor risk groups, respectively. This data shows that the outcome of patients was closely related with risk groups.
HR -Hazard ratio, CI -Confidence interval
According to new IGCCCG classification system, primary mediastinum-originated tumors, nonpulmonary visceral metastases or the presence of elevated tumor markers were associated with poor prognosis.
Mediastinum-originated tumors were shown to have the worst prognosis and the prognosis for retroperitoneum originated germ cell tumors is accepted as intermediate risk.
[1] Patients with metastasis other than lung have been reported to have a five-year survival of less than of 18 months due to progression. Our study showed that persistent elevation of serum tumor markers was a significant prognostic factor in univariate analysis (P<0.001) but not in multivariate analysis (p: 0.59).
In summary, although our study retrospectively examined the patients most of whom underwent their surgery at different centers, their survival rates according to risk groups are similar to the current literature data and the outcome of patients with advanced stage nonseminomatous germ cell tumors is closely related with the localization site and the relapse site of the tumor. Further large prospective randomized studies may identify different prognostic factors in these patients along with responsiveness to different chemotherapy regimens applicable in poor risk patients.
Our study also revealed that patients with References tumors of extragonadal origin (22% of all patients) had poor prognosis; and mediastinum-originated tumors had prognosis. [20] In our study, the cut-off value was 1987;47:2714-8. 9.
Fleming ID, Cooper JS, Henson DE. AJCC cancer staging manual, 50%.
accepted as 1000 U/ml and 10.000 mU/ml for AFP and β-HCG, respectively. On these values, these tumor markers were found to be important prognostic factors by only univariate analysis (p: 0.001 and P<0.001).
Persistent elevation of serum tumor markers was estimated to be crucial in assessing the refractoriness of tumor to treatment and the risk of relapse.
[21] In our study, 11 patients had persistent serum tumor marker elevation; and all of them have died at a median time 
